What is it about?
In this work, we explore a new way to understand and potentially produce peptide-based medicines, focusing on GLP-1/GIP analogue peptides used to treat type 2 diabetes and obesity. We report the crystal structure of this type of peptide in its free (unbound) form. By growing crystals and analysing them at high resolution, we show how the peptide molecules arrange themselves into an ordered, spiral-like structure, and identify the key interactions that hold this structure together.
Featured Image
Photo by Trophim Laptev on Unsplash
Why is it important?
GLP-1 and GIP analogue peptides are an important and rapidly growing class of medicines, but they are difficult and expensive to manufacture. Current purification methods are often slow and inefficient. By determining this crystal structure, we provide new insight into how these peptides behave and interact at the molecular level. This helps address a key gap in understanding, particularly for peptides in their unbound form. This knowledge is important because it can help guide the development of improved purification strategies (such as crystallisation) and support more efficient manufacturing of these medicines.
Perspectives
From a personal perspective, this work has been particularly rewarding. We believe this is the first time an unbound, acylated GLP-1 analogue peptide has been crystallised and structurally characterised, which makes it an exciting step forward for the field. It was also a valuable opportunity to collaborate with researchers at Eli Lilly and Company, bringing together different areas of expertise to tackle a challenging problem. Beyond this, I am especially interested in where this work can lead. There is clear potential to explore whether similar crystallisation approaches can be applied to other GLP-1 analogues and related peptide medicines, particularly those already in clinical use. Understanding how modifications such as acylation influence crystal formation will be an important next step. More broadly, I hope this study encourages others to look again at crystallisation as a practical tool for peptide purification. If we can build on these findings, there is real potential to make the production of these important medicines more efficient, and ultimately more accessible.
Hamish Mitchell
University College London
Read the Original
This page is a summary of: Crystallization and 1.6 Å resolution crystal structure of an acylated GLP-1/GIP analogue peptide, Acta Crystallographica Section F Structural Biology Communications, March 2026, International Union of Crystallography,
DOI: 10.1107/s2053230x26001937.
You can read the full text:
Contributors
The following have contributed to this page
